180 related articles for article (PubMed ID: 32755678)
1. Structure activity study of S-trityl-cysteamine dimethylaminopyridine derivatives as SIRT2 inhibitors: Improvement of SIRT2 binding and inhibition.
Radwan MO; Ciftci HI; Ali TFS; Koga R; Tateishi H; Nakata A; Ito A; Yoshida M; Fujita M; Otsuka M
Bioorg Med Chem Lett; 2020 Oct; 30(19):127458. PubMed ID: 32755678
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative
Radwan MO; Ciftci HI; Ali TFS; Ellakwa DE; Koga R; Tateishi H; Nakata A; Ito A; Yoshida M; Okamoto Y; Fujita M; Otsuka M
Molecules; 2019 Sep; 24(18):. PubMed ID: 31510043
[No Abstract] [Full Text] [Related]
3. Hit-to-lead optimization on aryloxybenzamide derivative virtual screening hit against SIRT.
Yagci S; Gozelle M; Kaya SG; Ozkan Y; Aksel AB; Bakar-Ates F; Dundar Y; Eren G
Bioorg Med Chem; 2021 Jan; 30():115961. PubMed ID: 33360574
[TBL] [Abstract][Full Text] [Related]
4. Ligand-based design and synthesis of new trityl histamine and trityl cysteamine derivatives as SIRT2 inhibitors for cancer therapy.
Badran MM; Abbas SH; Tateishi H; Maemoto Y; Toma T; Ito A; Fujita M; Otsuka M; Abdel-Aziz M; Radwan MO
Eur J Med Chem; 2024 Apr; 269():116302. PubMed ID: 38484678
[TBL] [Abstract][Full Text] [Related]
5. X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.
Yang LL; Wang HL; Zhong L; Yuan C; Liu SY; Yu ZJ; Liu S; Yan YH; Wu C; Wang Y; Wang Z; Yu Y; Chen Q; Li GB
Eur J Med Chem; 2018 Jul; 155():806-823. PubMed ID: 29957526
[TBL] [Abstract][Full Text] [Related]
6. Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activity-Dependent Inhibition, and On-Target Anticancer Activities.
Spiegelman NA; Price IR; Jing H; Wang M; Yang M; Cao J; Hong JY; Zhang X; Aramsangtienchai P; Sadhukhan S; Lin H
ChemMedChem; 2018 Sep; 13(18):1890-1894. PubMed ID: 30058233
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of certain benzothieno[3,2-d]pyrimidine derivatives as a selective SIRT2 inhibitors.
Khalil NA; Ahmed EM; Zaher AF; El-Zoghbi MS; Sobh EA
Eur J Med Chem; 2020 Feb; 187():111926. PubMed ID: 31812033
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and evaluation of a novel prodrug, a S-trityl-
Fukai R; Ogo N; Ichida T; Yamane M; Sawada JI; Miyoshi N; Murakami H; Asai A
Eur J Med Chem; 2021 Apr; 215():113288. PubMed ID: 33640763
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
Rodriguez D; Ramesh C; Henson LH; Wilmeth L; Bryant BK; Kadavakollu S; Hirsch R; Montoya J; Howell PR; George JM; Alexander D; Johnson DL; Arterburn JB; Shuster CB
Bioorg Med Chem; 2011 Sep; 19(18):5446-53. PubMed ID: 21855351
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
Sakai T; Matsumoto Y; Ishikawa M; Sugita K; Hashimoto Y; Wakai N; Kitao A; Morishita E; Toyoshima C; Hayashi T; Akiyama T
Bioorg Med Chem; 2015 Jan; 23(2):328-39. PubMed ID: 25515955
[TBL] [Abstract][Full Text] [Related]
11. Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure-Activity Relationship Analysis.
Huang S; Song C; Wang X; Zhang G; Wang Y; Jiang X; Sun Q; Huang L; Xiang R; Hu Y; Li L; Yang S
J Chem Inf Model; 2017 Apr; 57(4):669-679. PubMed ID: 28301150
[TBL] [Abstract][Full Text] [Related]
12. New SIRT2 inhibitors: Histidine-based bleomycin spin-off.
Ali TFS; Ciftci HI; Radwan MO; Koga R; Ohsugi T; Okiyama Y; Honma T; Nakata A; Ito A; Yoshida M; Fujita M; Otsuka M
Bioorg Med Chem; 2019 May; 27(9):1767-1775. PubMed ID: 30885568
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore modeling and virtual screening studies to identify novel selective SIRT2 inhibitors.
Eren G; Bruno A; Guntekin-Ergun S; Cetin-Atalay R; Ozgencil F; Ozkan Y; Gozelle M; Kaya SG; Costantino G
J Mol Graph Model; 2019 Jun; 89():60-73. PubMed ID: 30870650
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, in-vitro evaluation and molecular docking studies of novel indole derivatives as inhibitors of SIRT1 and SIRT2.
Manjula R; Gokhale N; Unni S; Deshmukh P; Reddyrajula R; Srinivas Bharath MM; Dalimba U; Padmanabhan B
Bioorg Chem; 2019 Nov; 92():103281. PubMed ID: 31561106
[TBL] [Abstract][Full Text] [Related]
15. The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model.
Di Fruscia P; Zacharioudakis E; Liu C; Moniot S; Laohasinnarong S; Khongkow M; Harrison IF; Koltsida K; Reynolds CR; Schmidtkunz K; Jung M; Chapman KL; Steegborn C; Dexter DT; Sternberg MJ; Lam EW; Fuchter MJ
ChemMedChem; 2015 Jan; 10(1):69-82. PubMed ID: 25395356
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors.
Yang L; Ma X; Yuan C; He Y; Li L; Fang S; Xia W; He T; Qian S; Xu Z; Li G; Wang Z
Eur J Med Chem; 2017 Jul; 134():230-241. PubMed ID: 28415012
[TBL] [Abstract][Full Text] [Related]
17. Selective SIRT2 inhibitors as promising anticancer therapeutics: An update from 2016 to 2020.
Roshdy E; Mustafa M; Shaltout AE; Radwan MO; Ibrahim MAA; Soliman ME; Fujita M; Otsuka M; Ali TFS
Eur J Med Chem; 2021 Nov; 224():113709. PubMed ID: 34303869
[TBL] [Abstract][Full Text] [Related]
18. A Glycoconjugated SIRT2 Inhibitor with Aqueous Solubility Allows Structure-Based Design of SIRT2 Inhibitors.
Hong JY; Price IR; Bai JJ; Lin H
ACS Chem Biol; 2019 Aug; 14(8):1802-1810. PubMed ID: 31373792
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Selective SIRT2 Inhibitor and Its Anti-breast Cancer Activity.
Shah AA; Ito A; Nakata A; Yoshida M
Biol Pharm Bull; 2016; 39(10):1739-1742. PubMed ID: 27725455
[TBL] [Abstract][Full Text] [Related]
20. Novel small molecule SIRT2 inhibitors induce cell death in leukemic cell lines.
Kozako T; Mellini P; Ohsugi T; Aikawa A; Uchida YI; Honda SI; Suzuki T
BMC Cancer; 2018 Aug; 18(1):791. PubMed ID: 30081901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]